Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

Publication ,  Journal Article
de Vos, S; Swinnen, LJ; Wang, D; Reid, E; Fowler, N; Cordero, J; Dunbar, M; Enschede, SH; Nolan, C; Petrich, AM; Ross, JA; Salem, AH; Zhou, L ...
Published in: Ann Oncol
September 1, 2018

BACKGROUND: Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination with bendamustine-rituximab (BR) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: BR was given for six cycles at standard doses. Intermittent and continuous oral venetoclax administration was explored at 50-1200 mg daily doses. Co-primary objectives included safety, pharmacokinetics (PKs), maximum-tolerated dose (MTD), and recommended phase II dose (RP2D); secondary objective was preliminary efficacy. RESULTS: Sixty patients were enrolled: 32 with follicular lymphoma, 22 with diffuse large B-cell lymphoma, and 6 with marginal zone lymphoma. Nausea (70%), neutropenia (68%), diarrhea (55%), and thrombocytopenia (52%) were the most frequent adverse events (AEs). Most common grade 3/4 AEs were neutropenia (60%) and lymphopenia (38%). Serious AEs were reported in 24 patients; the most frequent were febrile neutropenia and disease progression (8% each). Five patients died from either disease progression (n = 4) or respiratory failure (n = 1). MTD was not reached; RP2D for venetoclax-BR combination was established as 800 mg daily continuously. Venetoclax PK exposure with and without BR was comparable. For all patients, overall response rate was 65%. Median duration of overall response, overall survival, and progression-free survival was 38.3 months [95% confidence interval (CI) 10.4-NR], not yet reached, and 10.7 months (95% CI 4.3-21.0), respectively. CONCLUSIONS: This study established the safety profile of venetoclax in combination with BR, and results demonstrated tolerability and preliminary efficacy of the combination. Additional follow-up is needed to better determine the future role of BR plus venetoclax in the treatment of relapsed/refractory B-cell NHL. TRIAL REGISTERED: Clinicaltrials.gov, NCT01594229.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

September 1, 2018

Volume

29

Issue

9

Start / End Page

1932 / 1938

Location

England

Related Subject Headings

  • Sulfonamides
  • Salvage Therapy
  • Rituximab
  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Lymphoma, Non-Hodgkin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
de Vos, S., Swinnen, L. J., Wang, D., Reid, E., Fowler, N., Cordero, J., … Flowers, C. R. (2018). Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol, 29(9), 1932–1938. https://doi.org/10.1093/annonc/mdy256
Vos, S. de, L. J. Swinnen, D. Wang, E. Reid, N. Fowler, J. Cordero, M. Dunbar, et al. “Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.Ann Oncol 29, no. 9 (September 1, 2018): 1932–38. https://doi.org/10.1093/annonc/mdy256.
de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018 Sep 1;29(9):1932–8.
de Vos, S., et al. “Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.Ann Oncol, vol. 29, no. 9, Sept. 2018, pp. 1932–38. Pubmed, doi:10.1093/annonc/mdy256.
de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018 Sep 1;29(9):1932–1938.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

September 1, 2018

Volume

29

Issue

9

Start / End Page

1932 / 1938

Location

England

Related Subject Headings

  • Sulfonamides
  • Salvage Therapy
  • Rituximab
  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Lymphoma, Non-Hodgkin